« Back to Record
Citation APA

De Caluwé, A., Desmoulins, I., Cao, K.-A. L., Remouchamps, V., Baten, A., Longton, E., Peignaux, K., Joaquin Garcia, A., Venet, D., Arecco, L., Agostinetto, E., Nader-Marta, G., Denis, Z., Dhont, J., Kristanto, P., Catteau, X., Larsimont, D., Salgado, R., Poortmans, P., Stagg, J., Sotiriou, C., Piccart, M., Ignatiadis, M., Romano, E., & Buisseret, L. (2026). Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial. Nature medicine, 32(7), 2461-2472. doi:10.1038/s41591-026-04453-z


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/412628

De Caluwé, A., Desmoulins, I., Cao, K.-A. L., Remouchamps, V., Baten, A., Longton, E., Peignaux, K., Joaquin Garcia, A., Venet, D., Arecco, L., Agostinetto, E., Nader-Marta, G., Denis, Z., Dhont, J., Kristanto, P., Catteau, X., Larsimont, D., Salgado, R., Poortmans, P., Stagg, J., Sotiriou, C., Piccart, M., Ignatiadis, M., Romano, E., & Buisseret, L. (2026). Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial. Nature medicine, 32(7), 2461-2472. doi:10.1038/s41591-026-04453-z